Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP6109909B2 - Muscle enhancer - Google Patents
[go: Go Back, main page]

JP6109909B2 - Muscle enhancer - Google Patents

Muscle enhancer Download PDF

Info

Publication number
JP6109909B2
JP6109909B2 JP2015220824A JP2015220824A JP6109909B2 JP 6109909 B2 JP6109909 B2 JP 6109909B2 JP 2015220824 A JP2015220824 A JP 2015220824A JP 2015220824 A JP2015220824 A JP 2015220824A JP 6109909 B2 JP6109909 B2 JP 6109909B2
Authority
JP
Japan
Prior art keywords
muscle
fish
protein
fast
walleye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015220824A
Other languages
Japanese (ja)
Other versions
JP2016073292A (en
Inventor
二功 川端
二功 川端
辻 智子
智子 辻
貴文 水重
貴文 水重
太郎 岸田
太郎 岸田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissui Corp
Original Assignee
Nippon Suisan Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Suisan Kaisha Ltd filed Critical Nippon Suisan Kaisha Ltd
Publication of JP2016073292A publication Critical patent/JP2016073292A/en
Application granted granted Critical
Publication of JP6109909B2 publication Critical patent/JP6109909B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00Working-up of proteins for foodstuffs
    • A23J3/04Animal proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

本発明は、筋肉増強剤に関する。また、本発明は、筋肉増強作用を有する食品に関する。   The present invention relates to a muscle enhancer. Moreover, this invention relates to the foodstuff which has a muscle enhancement effect.

筋肉は、タンパク質の摂取を増加することにより、効果的に増強されることが知られている。このため、種々のタンパク質を含有する筋肉増強剤が研究されている。たとえば、牛肉抽出物は、遅筋と速筋の両方を増大させることが報告されている。また、牛肉抽出物は、速筋を遅筋タイプの筋線維に変化させる性質を有することも報告されている。(非特許文献1)。   It is known that muscle is effectively strengthened by increasing protein intake. For this reason, muscle strengthening agents containing various proteins have been studied. For example, beef extract has been reported to increase both slow and fast muscles. It has also been reported that beef extract has a property of changing fast muscles to slow muscle type muscle fibers. (Non-patent document 1).

また、食物にL-アルギニンを補うことにより、遅筋と速筋の両方を増大させることが報告されている(非特許文献2)。   In addition, it has been reported that supplementing food with L-arginine increases both slow and fast muscles (Non-patent Document 2).

筋肉は、瞬発的な収縮の可能な速筋線維(白筋)と持続的な収縮の可能な遅筋線維(赤筋)に分類される。速筋は、すばやく収縮することが出来るため瞬発力を引き出す時に使われる。そして、速筋は無酸素運動の時によく使われる筋肉であり、その色から白筋とも言われている。遅筋は、小さな筋肉であり、ゆっくり収縮して持久力を引き出すときに使われる。そして、遅筋は、有酸素運動の時によく使われる筋肉であり、その色から赤筋とも言われている。運動の種類により使用される筋肉も異なるため、いずれかのタイプの筋肉を特異的に増強することができる食品が望まれている。しかし、速筋または遅筋のいずれかを特異的に増強することができる食品および薬剤は知られていない。さらに、遅筋を速筋タイプの筋線維に変化させることができる薬剤や食品成分も報告されていない。   Muscles are classified into fast muscle fibers (white muscle) that can instantaneously contract and slow muscle fibers (red muscle) that can continuously contract. The fast muscle can be quickly contracted and is used to extract the instantaneous force. The fast muscle is a muscle often used during anaerobic exercise, and it is also called a white muscle because of its color. Slow muscles are small muscles that are used to slowly contract and draw endurance. The slow muscle is a muscle often used during aerobic exercise, and it is also called red muscle because of its color. Since the muscles used differ depending on the type of exercise, a food that can specifically strengthen any type of muscle is desired. However, foods and drugs that can specifically enhance either fast or slow muscle are not known. In addition, no drug or food ingredient that can change the slow muscle into a fast muscle type muscle fiber has been reported.

一方、魚介類由来のタンパク質は、生体に対して種々の作用を有することが知られており、多くの魚介類由来のタンパク質について、その生体における効果が研究されてきた。たとえば、魚肉タンパク質の摂取により、内臓脂肪の蓄積が抑制されることがわかっている(特許文献1)。また、魚介類由来のタンパク質は、脂質代謝を改善することが知られている。たとえば、魚介類由来のタンパク質が、血中コレステロール低下効果を有することが記載されている(特許文献2)。その他にも、魚肉由来のタンパク質について、その生体における効果が研究されている。たとえば、スケトウダラ由来タンパク質は、コレステロールおよびトリグリセロールに対して影響を及ぼすことが報告されており(非特許文献3)、スケトウダラ由来タンパク質を与えたラットでは、カゼインを与えたラットと比較して、血漿中のトリグリセロール濃度が低くなることや、肝臓におけるコレステリルエステルの濃度が高くなることなどが示されている。   On the other hand, fish and shellfish-derived proteins are known to have various actions on living organisms, and many fish and shellfish-derived proteins have been studied for their effects on the organism. For example, it has been found that the intake of fish protein suppresses the accumulation of visceral fat (Patent Document 1). In addition, fish and shellfish-derived proteins are known to improve lipid metabolism. For example, it is described that fish and shellfish-derived proteins have a blood cholesterol lowering effect (Patent Document 2). In addition, fish-derived proteins have been studied for their effects in the living body. For example, walleye pollack-derived protein has been reported to have an effect on cholesterol and triglycerol (Non-patent Document 3), and in rats fed with walleye pollen-derived protein, plasma was compared with rats fed casein. It has been shown that the concentration of triglycerol in the medium decreases and the concentration of cholesteryl ester in the liver increases.

国際公開公報第2007/069716号International Publication No. 2007/069716 特開2010-95456号公報JP 2010-95456 JP

Hiroyuki Yoshihara et al.、“Beef Extract Supplementation Increase Leg Muscle Mass and Modifies Skeletal Muscle Fiber Types in Rats”、J Nutr Sci Vitaminol、2006年、52巻、p.183-193Hiroyuki Yoshihara et al., “Beef Extract Supplementation Increase Leg Muscle Mass and Modifies Skeletal Muscle Fiber Types in Rats”, J Nutr Sci Vitaminol, 2006, 52, p.183-193 Wenjuan Jobgen et al.、“Dietary L-Arginine Supplementation Reduces White Fat Gain and Enhances Skeletal Muscle and Brown Fat Masses in Diet-Induced Obese Rats”、The Journal of Nutrition、2009年、139巻、p.230-237Wenjuan Jobgen et al., “Dietary L-Arginine Supplementation Reduces White Fat Gain and Enhances Skeletal Muscle and Brown Fat Masses in Diet-Induced Obese Rats”, The Journal of Nutrition, 2009, 139, p.230-237. Anjali Shukla et al.、“Dietary fish protein alters blood lipid concentrations and hepatic genes involved in cholesterol homeostasis in the rat model”、British Journal of Nutrition、2006年、96巻、p.674-682Anjali Shukla et al., “Dietary fish protein alters blood lipid concentrations and hepatic genes involved in cholesterol homeostasis in the rat model”, British Journal of Nutrition, 2006, 96, p.674-682

本発明は、タラ目に属する魚の魚肉タンパク質を含有する筋肉増強剤を提供することを目的とする。また、本発明は、筋肉増強作用を有する食品を提供することを目的とする。   An object of this invention is to provide the muscle strengthening agent containing the fish meat protein of the fish which belongs to the order of Cod. Another object of the present invention is to provide a food having muscle strengthening action.

本発明者らは、スケトウダラ魚肉タンパク質が生理作用に及ぼす効果に注目し、研究を重ねた結果、スケトウダラ魚肉タンパク質が筋肉増強作用を有することを見いだし、本発明に想到した。   The present inventors paid attention to the effect of walleye pollock fish meat protein on the physiological action and, as a result of repeated research, found that walleye pollock fish meat protein has a muscle-enhancing action and arrived at the present invention.

すなわち、本発明は、タラ目に属する魚の魚肉タンパク質を含有する速筋特異的な筋肉増強剤を提供する。   That is, the present invention provides a fast muscle-specific muscle enhancer containing fish protein of fish belonging to the order of Cod.

また、本発明は、タラ目に属する魚の魚肉タンパク質を含有する、遅筋を速筋タイプに変化させる筋肉増強剤を提供する。   The present invention also provides a muscle-enhancing agent that contains fish protein of fish belonging to the order of Codidae and changes the slow muscle to the fast muscle type.

また、本発明は、タラ目に属する魚の魚肉タンパク質を含有し、速筋特異的な筋肉増強作用を有する旨の表示または遅筋を速筋に変化させる作用を有する旨の表示を付した食品(機能性食品)を提供する。   The present invention also includes a food protein containing fish protein of a fish belonging to the order of a cod, and a label indicating that it has a fast muscle-specific muscle-enhancing action or a label indicating that the slow muscle is changed to a fast muscle ( Functional food).

また、本発明は、速筋特異的な筋肉増強作用を有する旨の表示または遅筋を速筋に変化させる作用を有する旨の表示を付した食品を製造するための、タラ目に属する魚の魚肉タンパク質の使用を提供する。   The present invention also relates to a fish meat belonging to the order of a fish for producing a food with an indication that it has a fast muscle-specific muscle-enhancing effect or an indication that it has an action of changing a slow muscle to a fast muscle. Provide protein use.

また、本発明は、タラ目に属する魚の魚肉タンパク質を含有する食品を、前記食品が速筋特異的な筋肉増強作用を有すること、または遅筋を速筋に変化させる作用を有することを記載した説明書と共にパッケージした製品を提供する。   In addition, the present invention describes a food containing fish protein of a fish belonging to the order of the cod, that the food has a muscle strengthening action specific to fast muscles or an action to change slow muscles to fast muscles. Provide products packaged with instructions.

本発明の筋肉増強剤は、速筋特異的に筋肉を増強することができる。また、本発明の筋肉増強剤は、遅筋を速筋タイプに変化させることができる。   The muscle-enhancing agent of the present invention can strengthen muscles specifically for fast muscles. Moreover, the muscle strengthening agent of this invention can change a slow muscle to a fast muscle type.

本発明の筋肉増強剤は、瞬発力を必要とするアスリート向けに、栄養補給用ドリンクや食品として有用である。また、加齢に伴う筋量および筋力低下(サルコペニア)の予防におよび/または改善のための各種ドリンクや各種食品として有用である。   The muscle strengthening agent of the present invention is useful as a nutritional supplement drink or food for athletes who need instantaneous power. It is also useful as various drinks and various foods for preventing and / or improving muscle mass and muscle weakness (sarcopenia) associated with aging.

スケトウダラ魚肉タンパク質によるひふく筋増強作用を示す図。The figure which shows the scuffing muscle reinforcement | strengthening effect by walleye pollock fish protein. スケトウダラ魚肉タンパク質によるヒラメ筋の重量変化を示す図。The figure which shows the weight change of the soleus muscle by walleye pollock fish meat protein. スケトウダラ魚肉タンパク質およびホキ魚肉タンパク質によるひふく筋の重量変化を示す図。The figure which shows the weight change of the scissors muscle by walleye pollock fish protein and Hoki fish protein. スケトウダラ魚肉タンパク質およびホキ魚肉タンパク質の投与による長趾伸筋の重量変化を示す図。The figure which shows the weight change of a long-knee extensor muscle by administration of walleye pollack fish protein and Hoki fish meat protein. スケトウダラ魚肉タンパク質およびホキ魚肉タンパク質の投与によるヒラメ筋の重量変化を示す図。The figure which shows the weight change of a soleus muscle by administration of walleye pollack fish protein and Hoki fish meat protein. スケトウダラ魚肉タンパク質の投与によるMyh4遺伝子の発現量の変化を示す図。The figure which shows the change of the expression level of Myh4 gene by administration of walleye pollock fish meat protein. スケトウダラ魚肉タンパク質の投与によるMyh7遺伝子の発現量の変化を示す図。The figure which shows the change of the expression level of the Myh7 gene by administration of walleye pollock fish meat protein. スケトウダラ魚肉タンパク質の投与によるPGC1α遺伝子の発現量の変化を示す図。The figure which shows the change of the expression level of PGC1 (alpha) gene by administration of walleye pollack fish meat protein. スケトウダラ魚肉タンパク質の投与によるGLUT4遺伝子の発現量の変化を示す図。The figure which shows the change of the expression level of GLUT4 gene by administration of walleye pollock fish protein. スケトウダラ魚肉タンパク質の投与による血糖値変化を示す図。The figure which shows the blood glucose level change by administration of walleye pollack fish meat protein. スケトウダラ魚肉タンパク質、大豆タンパク質、卵白タンパク質、カゼインおよびホエイによるひふく筋の重量変化を示す図。The figure which shows the weight change of the calf muscle by walleye pollock fish meat protein, soybean protein, egg white protein, casein, and whey. スケトウダラ魚肉タンパク質、大豆タンパク質、卵白タンパク質、カゼインおよびホエイの投与による長趾伸筋の重量変化を示す図。The figure which shows the weight change of the long calf extensor muscle by administration of walleye pollack fish protein, soybean protein, egg white protein, casein, and whey. スケトウダラ魚肉タンパク質、大豆タンパク質、卵白タンパク質、カゼインおよびホエイの投与によるヒラメ筋の重量変化を示す図。The figure which shows the weight change of the soleus muscle by administration of walleye pollack fish protein, soybean protein, egg white protein, casein, and whey.

以下、本発明の筋肉増強剤について説明する。本発明の筋肉増強剤は、タラ目に属する魚の魚肉タンパク質を含む。   Hereinafter, the muscle enhancing agent of the present invention will be described. The muscle strengthening agent of the present invention contains fish protein of fish belonging to the order of Cod.

本発明において、魚肉タンパク質は、魚肉そのものであってもよいが、脱脂処理により脂質を除いたものも用いることができる。脱脂方法としては、煮る、蒸す、焼くといった方法や、エタノールまたはヘキサンなどを使用して抽出するなどの方法を使用することができる。たとえば、魚肉タンパク質として、以下の工程で処理したスケトウダラ魚肉およびホキ魚肉を使用することができる。スケトウダラ魚肉を適当な大きさに切断し、切断した試料を凍結させた後、凍結乾燥機にて凍結乾燥させる。凍結乾燥した試料を常法にて粉砕し、これにエタノール等を添加して脂溶性成分を溶出させる。次いで、エタノールを除去することによりスケトウダラ魚肉タンパク質を得ることができる。脱脂処理により脂質を除いた場合は、摂取エネルギーを減少させることができる。   In the present invention, the fish meat protein may be the fish meat itself, but it is also possible to use a protein obtained by removing lipids by degreasing treatment. As a degreasing method, a method such as boiling, steaming or baking, or a method such as extraction using ethanol or hexane can be used. For example, walleye pollack fish and Hoki fish meat processed in the following steps can be used as fish meat protein. The walleye pollock fish meat is cut into an appropriate size, the cut sample is frozen, and then freeze-dried in a freeze dryer. The freeze-dried sample is pulverized by a conventional method, and ethanol or the like is added thereto to elute the fat-soluble component. Next, by removing ethanol, walleye fish protein can be obtained. When lipid is removed by degreasing, the intake energy can be reduced.

また、魚肉タンパク質は、吸収しやすいように分解して使用することもできる。たとえば、パパイン、トリプシン、ペプシン、ブロメライン、フィシンおよびアルカラーゼプロテアーゼなどのタンパク質分解酵素を使用して分解することができる。   Fish meat protein can also be decomposed and used so that it can be easily absorbed. For example, it can be degraded using proteolytic enzymes such as papain, trypsin, pepsin, bromelain, ficin and alcalase protease.

本発明において、原料となる魚肉は、白身が好ましく、特にタラ目に属する魚の魚肉タンパク質が好ましい。具体的には、タラ目に属する魚の例には、スケトウダラ、ミナミダラ、ノーザンブルーホワイティング、キングクリップ、メルルーサ、マダラおよびホキなどを含む。   In the present invention, the fish meat used as a raw material is preferably white meat, and particularly fish protein of fish belonging to the order of the cod. Specifically, examples of fish belonging to the order of Codella include walleye pollock, southern bluefin, northern blue whiting, king clip, hake, madara and hoki.

本明細書において、筋肉増強とは、筋肉量を増加することを意味する。筋肉は、瞬発的な収縮の可能な速筋線維(白筋)と持続的な収縮の可能な遅筋線維(赤筋)に分類されるが、本発明の筋肉増強剤は、速筋特異的に筋肉を増強する。本明細書において、速筋特異的な筋肉増強とは、種々のタンパク質と比較したときに、増加される全筋肉量のうち、速筋の筋肉量がより多く増加されることを意味する。したがって、速筋特異的な筋肉増強であっても、遅筋も同時に増強される。   As used herein, muscle augmentation means increasing muscle mass. Muscles are classified into fast muscle fibers capable of instantaneous contraction (white muscles) and slow muscle fibers capable of continuous contraction (red muscles). The muscle-enhancing agent of the present invention is fast muscle-specific. To strengthen muscles. In the present specification, fast muscle-specific muscle enhancement means that the muscle mass of fast muscle is increased more than the total muscle mass increased when compared with various proteins. Therefore, even when muscle enhancement is specific to fast muscles, slow muscles are enhanced at the same time.

また、本発明の筋肉増強剤は、遅筋を速筋タイプに変化させる作用を有する。本明細書において、遅筋を速筋タイプに変化させるとは、遅筋の比率と速筋の比率を比較したときに、遅筋の比率が減少し、速筋の比率が増大することをいう。   Moreover, the muscle strengthening agent of this invention has the effect | action which changes a slow muscle to a fast muscle type. In this specification, changing the slow muscle to the fast muscle type means that when the ratio of the slow muscle and the ratio of the fast muscle are compared, the ratio of the slow muscle decreases and the ratio of the fast muscle increases. .

本発明の速筋特異的な筋肉増強剤および遅筋を速筋タイプに変化させる筋肉増強剤は、上記の成分に加えて、任意の成分を含む組成物であることができる。たとえば、本発明の速筋特異的な筋肉増強剤は、医薬として使用される場合、薬学的に許容される基剤、担体、賦形剤、崩壊剤、滑沢剤および着色剤などと共に医薬組成物として提供することができる。医薬組成物に使用する担体および賦形剤の例には、乳糖、ブドウ糖、白糖、マンニトール、馬鈴薯デンプン、トウモロコシデンプン、炭酸カルシウム、リン酸カルシウム、硫酸カルシウムおよび結晶セルロースなどを含む。また、結合剤の例には、デンプン、ゼラチン、シロップ、トラガントゴム、ポリビニルアルコール、ポリビニルエーテル、ポリビニルピロリドン、ヒドロキシプロピルセルロース、メチルセルロース、エチルセルロースおよびカルボキシメチルセルロースなどを含む。また、崩壊剤の例には、デンプン、寒天、ゼラチン末、結晶セルロース、炭酸カルシウム、炭酸水素ナトリウム、アルギン酸ナトリウム、カルボキシメチルセルロースナトリウムおよびカルボキシメチルセルロースカルシウムなどを含む。また、滑沢剤の例には、ステアリン酸マグネシウム、水素添加植物油、タルクおよびマクロゴールなどを含む。また、着色剤は、医薬品に添加することが許容されている任意の着色剤を使用することができる。また、医薬組成物は、必要に応じて、白糖、ゼラチン、精製セラック、ゼラチン、グリセリン、ソルビトール、エチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、フタル酸セルロースアセテート、ヒドロキシプロピルメチルセルロースフタレート、メチルメタクリレートおよびメタアクリル酸重合体などで一層以上の層で被膜してもよい。また、必要に応じて、pH調節剤、緩衝剤、安定化剤および可溶化剤などを添加してもよい。   The fast muscle-specific muscle-enhancing agent of the present invention and the muscle-enhancing agent that changes the slow muscle to the fast muscle type can be a composition containing an optional component in addition to the above components. For example, the fast muscle-specific muscle-enhancing agent of the present invention, when used as a medicament, has a pharmaceutical composition together with a pharmaceutically acceptable base, carrier, excipient, disintegrant, lubricant and coloring agent. Can be provided as a product. Examples of carriers and excipients used in the pharmaceutical composition include lactose, glucose, sucrose, mannitol, potato starch, corn starch, calcium carbonate, calcium phosphate, calcium sulfate and crystalline cellulose. Examples of the binder include starch, gelatin, syrup, tragacanth gum, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, hydroxypropylcellulose, methylcellulose, ethylcellulose and carboxymethylcellulose. Examples of the disintegrant include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, sodium alginate, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium and the like. Examples of lubricants include magnesium stearate, hydrogenated vegetable oil, talc and macrogol. As the colorant, any colorant allowed to be added to a pharmaceutical product can be used. The pharmaceutical composition may be sucrose, gelatin, purified shellac, gelatin, glycerin, sorbitol, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, cellulose phthalate acetate, hydroxypropylmethylcellulose phthalate, methyl methacrylate as necessary. Further, it may be coated with one or more layers with a methacrylic acid polymer or the like. Moreover, you may add a pH adjuster, a buffering agent, a stabilizer, a solubilizer, etc. as needed.

また、医薬組成物は、任意の形態の製剤として提供することができる。たとえば、医薬組成物は、経口投与製剤として、糖衣錠、バッカル錠、コーティング錠およびチュアブル錠等の錠剤、トローチ剤、丸剤、散剤およびソフトカプセルを含むカプセル剤、顆粒剤、懸濁剤、乳剤、ドライシロップを含むシロップ剤、エリキシル剤等の液剤であることができる。また、医薬組成物は、非経口投与のために、静脈注射、皮下注射、腹腔内注射、筋肉内注射、経皮投与、経鼻投与、経肺投与、経腸投与、口腔内投与および経粘膜投与などの投与のための製剤であることができる。たとえば、注射剤、経皮吸収テープ、エアゾール剤および坐剤などであることができる。   In addition, the pharmaceutical composition can be provided as a preparation in any form. For example, the pharmaceutical composition can be prepared as an orally administered preparation, such as a sugar-coated tablet, buccal tablet, coated tablet and chewable tablet, capsules including troches, pills, powders and soft capsules, granules, suspensions, emulsions and dry syrups. It can be a liquid such as syrup and elixir. In addition, the pharmaceutical composition can be administered intravenously, subcutaneously, intraperitoneally, intramuscularly, transdermally, nasally, pulmonarily, enterally, buccally, and transmucosally for parenteral administration. It can be a formulation for administration, such as administration. For example, it can be an injection, a transdermal absorption tape, an aerosol, a suppository and the like.

また、本発明の速筋特異的な筋肉増強剤および遅筋を速筋タイプに変化させる筋肉増強剤は、食品として提供することができる。すなわち、タラ目に属する魚の魚肉タンパク質を含有し、速筋特異的な筋肉増強作用および遅筋を速筋タイプに変化させる作用を有する食品が提供される。本発明において、食品は、飲料を含む食品全般を意味し、サプリメントなどの健康食品を含む一般食品の他、消費者庁の保健機能食品制度に規定される特定保健用食品や栄養機能食品をも含む。たとえば、速筋特異的な筋肉増強作用を有する旨の表示または遅筋を速筋タイプに変化させる作用を有する旨の表示を付した機能性食品が提供される。たとえば、タラ目に属する魚の魚肉タンパク質を含有する食品をそのまま提供することができる。また、他の食品に添加し、混合し、または塗布することなどにより、食品素材として、速筋特異的な筋肉増強作用および遅筋を速筋タイプに変化させる作用を付与した食品を提供することができる。食品の他に、化粧品および餌料などとして提供することもできる。   The fast muscle-specific muscle potentiator of the present invention and the muscle enhancer that changes the slow muscle into a fast muscle type can be provided as food. That is, a food containing fish meat protein of a fish belonging to the order of Cod and having an action of enhancing muscles specific to fast muscles and an action of changing slow muscles to a fast muscle type is provided. In the present invention, food means all foods including beverages, and includes general foods including health foods such as supplements, as well as foods for specified health use and nutritional function foods stipulated in the Health Function Food System of the Consumer Affairs Agency. Including. For example, a functional food with an indication that it has a fast muscle-specific muscle-enhancing effect or an indication that it has an effect of changing the slow muscle to a fast muscle type is provided. For example, a food containing fish protein of fish belonging to the order of Cod can be provided as it is. Also, to provide foods that are added to other foods, mixed or applied, etc., as food materials that have fast muscle-specific muscle strengthening action and action to change slow muscle to fast muscle type Can do. In addition to food, it can also be provided as cosmetics and food.

また、タラ目に属する魚の魚肉タンパク質を含有する食品を、当該食品が速筋特異的な筋肉増強作用を有すること、または遅筋を速筋タイプに変化させる作用を有することを記載した説明書と共にパッケージした製品として提供することができる。   In addition, a food containing fish meat protein of a fish belonging to Codidae, together with instructions describing that the food has a fast muscle-specific muscle-enhancing action or an action that changes the slow muscle to a fast-muscle type It can be provided as a packaged product.

また、上記のように速筋特異的な筋肉増強作用または遅筋を速筋タイプに変化させる作用を有する旨を有する旨の表示を付した食品を製造するために、タラ目に属する魚の魚肉タンパク質を使用することができる。本発明の筋肉増強剤、並びに食品には、限定されないが、速筋特異的な筋肉増強作用を奏するのに必要な量を含有することができる。本発明の筋肉増強剤、並びに食品は、任意の量でタラ目に属する魚の魚肉タンパク質を含むことができ、たとえば100μg〜0.999kg/kg、好ましくは10g〜900g/kgの量で含むことができる。   In addition, in order to produce a food with an indication that it has a fast muscle-specific muscle-enhancing action or an action that changes the slow muscle to a fast-muscle type as described above, fish protein of fish belonging to the cod eye Can be used. Although it is not limited to the muscle strengthening agent of this invention, and a foodstuff, it can contain the quantity required in order to show | play a muscle enhancement action specific to a fast muscle. The muscle-enhancing agent of the present invention, as well as food, can contain fish protein of fish belonging to the order of cod, for example, 100 μg to 0.999 kg / kg, preferably 10 g to 900 g / kg. .

また、タラ目に属する魚の魚肉タンパク質は、医薬として患者に投与する場合、症状の程度、患者の年齢、体重および健康状態などの条件に応じて、限定されないが、成人であれば100μg〜10g/kg/日、好ましくは0.1g〜1g/kg/日を経口または非経口的に、1日1回または2〜4回以上に分割して、適宜の間隔をあけて投与することができる。また、本発明に使用される魚肉タンパク質は、医薬品のように強力な効果や副作用を有するものではないので、1日の摂取量に制限はない。   In addition, the fish protein of the fish belonging to the order of Cod is not limited depending on conditions such as symptom degree, patient age, weight and health condition when administered to a patient as a medicine, but for adults, it is 100 μg to 10 g / kg / day, preferably 0.1 to 1 g / kg / day, can be administered orally or parenterally, divided into once or 2 to 4 times or more per day, and can be administered at appropriate intervals. In addition, the fish protein used in the present invention does not have a strong effect and side effects unlike pharmaceutical products, so there is no limit on the daily intake.

実施例1 本発明品による筋肉増強作用   Example 1 Muscle strengthening effect of the product of the present invention

冷凍のアラスカ産スケトウダラフィレー(ユニシー社製)をバンドソー(秋山機械社製、600ST)で1cm×1cm×1cm程度の大きさに切断した。切断した試料を凍結乾燥用トレーに一層に並べて、凍結乾燥機(東京理化器械社製、TF20-85ATNNN)にて-30℃で4時間の予備凍結後に、4昼夜凍結乾燥した。凍結乾燥試料を手で軽く砕き、ピンミル(槇野産業社製、EM-1A)にて粉砕した。粉砕した凍結乾燥試料に99.5%エタノール(和光純薬工業社製、試薬特級)を添加して脂溶性成分を溶出させた。1週間風乾させた後、残留エタノールをロータリーエバポレーター(東京理化器械社製、N-21NS)にて除去し、スケトウダラ魚肉タンパク質を得た。冷凍のスケトウダラフィレー10kgから、約1.5kgのスケトウダラ魚肉タンパク質が得られた。得られたスケトウダラ魚肉タンパク質の成分組成を表1に示す。   A frozen Alaskan walleye fillet (Unicy) was cut into a size of about 1 cm × 1 cm × 1 cm with a band saw (Akiyama Machine Co., Ltd., 600ST). The cut samples were arranged in one layer on a freeze-drying tray, and pre-freeze for 4 hours at −30 ° C. with a freeze dryer (manufactured by Tokyo Rika Kikai Co., Ltd., TF20-85ATNNN), followed by freeze-drying for 4 days and nights. The freeze-dried sample was lightly crushed by hand and pulverized with a pin mill (manufactured by Hadano Sangyo Co., Ltd., EM-1A). 99.5% ethanol (manufactured by Wako Pure Chemical Industries, Ltd., reagent grade) was added to the pulverized freeze-dried sample to elute the fat-soluble component. After air-drying for 1 week, residual ethanol was removed with a rotary evaporator (manufactured by Tokyo Rika Kikai Co., Ltd., N-21NS) to obtain a walleye fish protein. About 1.5 kg of walleye fish protein was obtained from 10 kg of frozen walleye fillet. The component composition of the resulting walleye fish protein is shown in Table 1.

5週齢の雄性SDラット(清水実験材料社より入手)を、スケトウダラ魚肉タンパク質群とカゼイン群に分け、それぞれ表2に示す組成の粉末飼料を自由摂食させた。尚、この粉末飼料は大石ら(Yoshie Oishi et al.、“Alaska pollack protein prevents the accumulation of visceral fat in rats fed a high fat diet”、J. Nutr. Sci. Vitaminol.、2009年、55巻、p.156-161)に記載の飼料と同様のものを用いた。また、カゼイン群の飼料に含まれるカゼインは、New Zealand Dairy Board社の物を用いた。一群は8匹のラットとし、ラットに飼料を4週間連続摂取させた後、解剖して組織重量を測定した。この時、ラットは一日あたり15〜30gの飼料を摂取していた。   Five-week-old male SD rats (obtained from Shimizu Experimental Materials Co., Ltd.) were divided into walleye fish meat protein group and casein group, and freely fed with powdered feed having the composition shown in Table 2, respectively. In addition, this powdered feed is obtained by Oishi et al. (Yoshie Oishi et al., “Alaska pollack protein prevents the accumulation of visceral fat in rats fed a high fat diet”, J. Nutr. Sci. Vitaminol., 2009, 55, p. The same feed as described in .156-161) was used. The casein contained in the feed of the casein group was from New Zealand Dairy Board. One group consisted of 8 rats, and the rats were ingested for 4 consecutive weeks, then dissected and the tissue weight was measured. At this time, the rats were ingesting 15-30 g of food per day.

結果
速筋の代表であるひふく筋重量を測定した結果を図1に示してある。カゼイン群と比べてスケトウダラ魚肉タンパク質群では速筋の代表であるひふく筋重量が有意に増加した。
Results FIG. 1 shows the result of measuring the weight of the puffer muscle, which is a representative of the fast muscles. Compared to the casein group, the weight of the calf muscle, which is representative of fast muscle, increased significantly in the walleye fish protein group.

一方、遅筋の代表であるヒラメ筋重量を測定した結果を図2に示してある。遅筋の代表であるヒラメ筋重量にはカゼイン群スとケトウダラ魚肉タンパク質群との間で差は見られなかった。   On the other hand, the result of measuring the weight of the soleus, which is representative of the slow muscle, is shown in FIG. There was no difference in the weight of the soleus muscle, which is representative of the slow muscle, between the casein group and the kettlefish fish protein group.

したがって、スケトウダラ魚肉タンパク質は速筋特異的な筋肉増強作用を有することが示された。   Therefore, it was shown that walleye pollock fish meat protein has a muscle strengthening action specific to fast muscles.

実施例2 本発明品のラット長期投与による筋肉増強作用、筋線維タイプ変化および筋肉代謝変化   Example 2 Muscle enhancement effect, muscle fiber type change and muscle metabolism change by long-term administration of the product of the present invention in rats

スケトウダラ魚肉タンパク質は、実施例1と同様の手順で得たものを使用した。また、ホキ魚肉タンパク質は、実施例1と同様の手順により、冷凍のニュージーランド産ホキフィレー(タリーズ社製)から得た。冷凍のホキフィレー10kgから、約1.6kgのホキ魚肉タンパク質が得られた。得られたホキ魚肉タンパク質の成分組成を表3に示す。   The walleye pollen fish protein used was obtained by the same procedure as in Example 1. Hoki fish meat protein was obtained from frozen New Zealand Hoki fillet (Tully's Co., Ltd.) in the same manner as in Example 1. About 1.6 kg of hoki fish protein was obtained from 10 kg of frozen hoki fillet. The component composition of the obtained hoki fish protein is shown in Table 3.

5週齢の雄性SDラット(清水実験材料社より入手)を、スケトウダラ魚肉タンパク質群、ホキ魚肉タンパク質群およびカゼイン群に分け、それぞれ表4に示す組成の粉末飼料を自由摂食させた。また、カゼイン群の飼料に含まれるカゼインは、New Zealand Dairy Board社の物を用いた。一群は10匹のラットとし、ラットに飼料を8週間連続摂取させた後、解剖して組織重量を測定した。この時、ラットは一日あたり15〜30gの飼料を摂取していた。   Five-week-old male SD rats (obtained from Shimizu Experimental Materials Co., Ltd.) were divided into walleye fish protein group, Hoki fish protein group, and casein group, and were fed freely with powdered feed having the composition shown in Table 4, respectively. The casein contained in the feed of the casein group was from New Zealand Dairy Board. One group consisted of 10 rats, and the rats were ingested for 8 weeks continuously, then dissected and the tissue weight was measured. At this time, the rats were ingesting 15-30 g of food per day.

スケトウダラ魚肉タンパク質群およびカゼイン群のラットの長趾伸筋とヒラメ筋からtotal RNAを抽出し、RT-PCR法によりMyh4、Myh7、PGC1α、GLUT4のmRNA量を定量した。同時にサイクロフィリンのmRNA量も定量し、比較のための内部標準とした。PCR反応に用いた各遺伝子のプライマー配列を表5に示す。   Total RNA was extracted from the longus and soleus muscles of rats of the walleye fish protein group and casein group, and the mRNA levels of Myh4, Myh7, PGC1α and GLUT4 were quantified by RT-PCR. At the same time, the amount of cyclophilin mRNA was quantified and used as an internal standard for comparison. Table 5 shows primer sequences of each gene used in the PCR reaction.

結果
速筋の代表であるひふく筋と長趾伸筋の重量を測定した結果を図3および図4に示してある。カゼイン群と比べてスケトウダラ魚肉タンパク質群およびホキ魚肉タンパク質群では、速筋の代表であるひふく筋および長趾伸筋の重量が有意に増加した。
Results FIG. 3 and FIG. 4 show the results of measuring the weight of the puffer muscle and the long calf extensor which are representative of the fast muscle. Compared to the casein group, the walleye pollack fish protein group and the hoki fish protein group significantly increased the weight of the puffer muscle and the long calf extensor muscle, which are representative of the fast muscle.

一方、遅筋の代表であるヒラメ筋重量を測定した結果を図5に示してある。カゼイン群と比べてスケトウダラ魚肉タンパク質群およびホキ魚肉タンパク質群では、遅筋の代表であるヒラメ筋の重量が増加する傾向が見られたが、有意な差は観察されなかった。   On the other hand, the result of measuring the weight of the soleus, which is representative of the slow muscle, is shown in FIG. Compared with the casein group, in the walleye fish protein group and the hoki fish protein group, the weight of the soleus muscle, which is representative of the slow muscle, tended to increase, but no significant difference was observed.

したがって、スケトウダラ魚肉タンパク質およびホキ魚肉タンパク質は、長期投与することにより、速筋特異的な筋肉増強作用を有することが示された。   Therefore, it was shown that walleye pollack fish protein and hoki fish meat protein have fast muscle-specific muscle-enhancing effects by long-term administration.

速筋の筋線維の指標であるMyh4遺伝子の測定結果を図6に示してある。Myh4遺伝子は、速筋の代表筋である長趾伸筋において、カゼイン群と比べてスケトウダラ魚肉タンパク質群では有意に発現量が増加していた。一方、遅筋の代表筋であるヒラメ筋においては、両群の間でMyh4遺伝子発現に差は見られなかった。   FIG. 6 shows the measurement results of the Myh4 gene, which is an index of fast muscle fibers. The expression level of the Myh4 gene was significantly increased in the walleye fish protein group compared to the casein group in the long-knee extensor muscle, which is a representative muscle of the fast muscle. On the other hand, in the soleus muscle, which is the representative muscle of the slow muscle, there was no difference in Myh4 gene expression between the two groups.

したがって、スケトウダラ魚肉タンパク質は、速筋をより速筋化させる方向に筋線維タイプを変化させることが推察された。   Therefore, it was inferred that walleye pollack fish meat protein changes the muscle fiber type in a direction to make fast muscles faster.

遅筋の筋線維の指標であるMyh7遺伝子の測定結果を図7に示してある。Myh7遺伝子は、ヒラメ筋において、カゼイン群と比べてスケトウダラ魚肉タンパク質群では有意に発現量が減少していた。一方、長趾伸筋においては、両群の間でMyh7遺伝子発現に差は見られなかった。   FIG. 7 shows the measurement results of the Myh7 gene, which is an indicator of slow muscle fibers. The expression level of the Myh7 gene was significantly decreased in the walleye fish protein group in the soleus muscle compared with the casein group. On the other hand, in the longus extensor, there was no difference in Myh7 gene expression between the two groups.

したがって、スケトウダラ魚肉タンパク質は、遅筋の筋線維を減らす方向に筋線維タイプを変化させることが推察された。   Therefore, it was speculated that walleye fish protein changes the muscle fiber type in the direction of decreasing slow muscle fibers.

脂質代謝亢進の指標であるPGC1α遺伝子の測定結果を図8に示してある。PGC1α遺伝子は、ヒラメ筋において、カゼイン群と比べてスケトウダラ魚肉タンパク質群では有意に発現量が減少していた。一方、長趾伸筋においては、両群の間でPGC1α遺伝子発現に差は見られなかった。   FIG. 8 shows the measurement results of the PGC1α gene, which is an index of hyperlipid metabolism. The expression level of PGC1α gene was significantly decreased in the walleye fish protein group in the soleus muscle compared with the casein group. On the other hand, there was no difference in the expression of PGC1α gene between the two groups in the longus extensor muscle.

また、糖質代謝亢進の指標であるGLUT4遺伝子の測定結果を図9に示してある。GLUT4遺伝子は、ヒラメ筋において、カゼイン群と比べてスケトウダラ魚肉タンパク質群では有意に発現量が増加していた。一方、長趾伸筋においては、両群の間でGLUT4遺伝子発現に差は見られなかった。   In addition, FIG. 9 shows the measurement results of the GLUT4 gene, which is an indicator of increased carbohydrate metabolism. The expression level of the GLUT4 gene was significantly increased in the walleye fish protein group in the soleus muscle compared with the casein group. On the other hand, in the longus extensor, there was no difference in GLUT4 gene expression between the two groups.

上記結果から、スケトウダラ魚肉タンパク質群では、糖質代謝が亢進されることが推察される。一般的に、遅筋では主に脂質を、速筋では主に糖質を消費することから、スケトウダラ魚肉タンパク質は、ヒラメ筋を遅筋型の代謝から速筋型の代謝へと変化させることが示された。Myh7遺伝子の変化を合わせて考えると、スケトウダラ魚肉タンパク質は、遅筋を速筋化させる方向に筋線維タイプを変化させることが推察された。   From the above results, it is inferred that carbohydrate metabolism is enhanced in the walleye fish protein group. In general, slow muscle consumes mainly lipids and fast muscle mainly consumes carbohydrates, so walleye fish protein can change soleus muscle from slow to fast muscle metabolism. Indicated. Considering the changes in the Myh7 gene, it was speculated that walleye fish protein changes the muscle fiber type in the direction that makes the slow muscle faster.

実施例3 ラット長期投与による血糖値上昇抑制作用   Example 3 Inhibition of blood glucose level increase by long-term administration in rats

5週齢の雄性SDラット(清水実験材料社より入手)を、スケトウダラ魚肉タンパク質群およびカゼイン群に分け、それぞれ表4と同様の組成の粉末飼料を自由摂食させた。また、カゼイン群の飼料に含まれるカゼインは、New Zealand Dairy Board社の物を用いた。一群は12匹のラットとし、ラットに飼料を5週間連続摂取させた。試験前日より10時間絶食させた後、40%グルコース溶液を体重100g当たり200mgの割合で投与した。投与前、投与後30分、60分、90分、120分の各時点において尾静脈より採血した。採血した血液を血糖値測定用チップ(ライフスキャン社製、One Touch Ultra)に吸収させ、血糖分析装置(ロシュ社製、ACCU-CHEK Active glucose meter)にて分析した。この時、ラットは、一日あたり15〜30gの飼料を摂取していた。   Five-week-old male SD rats (obtained from Shimizu Experimental Materials Co., Ltd.) were divided into walleye fish meat protein group and casein group, and each was freely fed a powdered feed having the same composition as in Table 4. The casein contained in the feed of the casein group was from New Zealand Dairy Board. One group consisted of 12 rats, and the rats were ingested for 5 consecutive weeks. After fasting for 10 hours from the day before the test, a 40% glucose solution was administered at a rate of 200 mg per 100 g body weight. Blood was collected from the tail vein at each time point before administration, 30 minutes, 60 minutes, 90 minutes, and 120 minutes after administration. The collected blood was absorbed into a blood sugar level measuring chip (Life Scan, One Touch Ultra) and analyzed with a blood sugar analyzer (Roche, ACCU-CHEK Active glucose meter). At this time, the rats were ingesting 15-30 g of food per day.

結果
糖負荷試験による血糖値変化の結果を図10に示してある。カゼイン群と比べてスケトウダラ魚肉タンパク質群では、有意に血糖値の上昇が抑制されていた。120分間の積分値の比較においても、カゼイン群と比べてスケトウダラ魚肉タンパク質群では有意に血糖値の上昇が抑制されることが確認された。
Results FIG. 10 shows the results of changes in blood glucose level by the glucose tolerance test. Compared with the casein group, the increase in blood glucose level was significantly suppressed in the walleye fish protein group. Also in the comparison of the integral value for 120 minutes, it was confirmed that the increase in blood sugar level was significantly suppressed in the walleye fish protein group compared with the casein group.

したがって、スケトウダラ魚肉タンパク質には、血糖値の上昇を抑制する作用があることが示された。スケトウダラ魚肉タンパク質の長期投与により、遅筋が速筋化する方向へ筋線維タイプが変化し、筋肉での糖質利用が高まった結果、血糖値の低下が惹起されたと推察される。   Therefore, it was demonstrated that walleye fish protein has an action of suppressing an increase in blood glucose level. It is inferred that the long-term administration of walleye pollock fish protein changed the muscle fiber type in the direction that the slow muscles become faster, and increased the utilization of carbohydrates in the muscles, resulting in a decrease in blood glucose level.

実施例4 本発明品のラット長期投与による筋肉増強作用の他タンパク質との比較   Example 4 Comparison with other proteins of muscle enhancement by long-term administration of the product of the present invention in rats

5週齢の雄性SDラット(清水実験材料社より入手)を、スケトウダラ魚肉タンパク質群、大豆タンパク質群、卵白タンパク質群、カゼイン群、およびホエイ群に分け、それぞれ表6に示した組成の粉末飼料を自由摂食させた。大豆タンパク質群の飼料に含まれる大豆タンパク質は、不二製油社の物を用いた。卵白タンパク質群の飼料に含まれる卵白タンパク質は、第一化成社の物を用いた。ホエイ群の飼料に含まれるホエイは、第一化成社の物を用いた。カゼイン群の飼料に含まれるカゼインは、New Zealand Dairy Board社の物を用いた。また、一群は10匹のラットとし、ラットに飼料を8週間連続摂取させた後、解剖して組織重量を測定した。この時、ラットは一日あたり15〜30gの飼料を摂取していた。   5-week-old male SD rats (obtained from Shimizu Experimental Materials Co., Ltd.) were divided into walleye fish protein group, soy protein group, egg white protein group, casein group, and whey group. Ad libitum. As a soy protein contained in the soy protein group feed, a product of Fuji Oil Co., Ltd. was used. The egg white protein contained in the feed of the egg white protein group was a product of Daiichi Kasei Co., Ltd. The whey contained in the whey group feed was Daiichi Kasei Corporation. Casein contained in the casein group feed was from New Zealand Dairy Board. One group consisted of 10 rats, and the rats were ingested for 8 weeks continuously, then dissected and the tissue weight was measured. At this time, the rats were ingesting 15-30 g of food per day.

結果
速筋の代表であるひふく筋と長趾伸筋の重量を測定した結果を図11および図12に示してある。カゼイン群と比べてスケトウダラ魚肉タンパク質群では、速筋の代表であるひふく筋および長趾伸筋の重量が有意に増加した。また、ホエイ群と比べてスケトウダラ魚肉タンパク質群では、長趾伸筋の重量が有意に増加した。大豆タンパク質群および卵白タンパク質群と比べてスケトウダラ魚肉タンパク質群では、ひふく筋と長趾伸筋の重量が増大する傾向が見られたが、有意な差は観察されなかった。
Results FIG. 11 and FIG. 12 show the results of measuring the weight of the puffer muscle and the long ankle extensor, which are representative of the fast muscles. Compared with the casein group, the walleye fish protein group significantly increased the weights of the gluteal and long-knee extensor muscles, which are representative of the fast muscles. In addition, in the walleye fish protein group, the weight of the long rib extensor was significantly increased compared to the whey group. Compared to the soy protein group and the egg white protein group, the walleye fish protein group showed a tendency to increase the weight of the puffer muscle and the long extensor muscle, but no significant difference was observed.

一方、遅筋の代表であるヒラメ筋重量を測定した結果を図13に示してある。ホエイ群と比べてスケトウダラ魚肉タンパク質群では、遅筋の代表であるヒラメ筋の重量が有意に増加した。大豆タンパク質群、卵白タンパク質群、カゼイン群と比べてスケトウダラ魚肉タンパク質群では、ヒラメ筋の重量が増大する傾向が見られたが、有意な差は観察されなかった。   On the other hand, the result of measuring the weight of the soleus, which is representative of the slow muscle, is shown in FIG. Compared to the whey group, the walleye fish protein group significantly increased the weight of the soleus muscle, which is representative of the slow muscle. Compared with the soy protein group, egg white protein group, and casein group, the walleye fish protein group tended to increase the weight of the soleus muscle, but no significant difference was observed.

したがって、スケトウダラ魚肉タンパク質は、長期投与することにより、大豆タンパク質、卵白タンパク質、カゼイン、ホエイの各タンパク質よりも強力な筋肉増強作用を有することが示された。   Therefore, it was shown that walleye pollack fish meat protein has a stronger muscle-enhancing action than soybean protein, egg white protein, casein, and whey proteins after long-term administration.

Claims (4)

タラ目に属する魚の魚肉タンパク質又は前記魚肉タンパク質のタンパク質分解酵素分解物を含有する、速筋特異的な筋肉増強用食品組成物。   A fast muscle-specific food composition for muscle enhancement, comprising fish protein of a fish belonging to the order of Cod or a proteolytic enzyme degradation product of said fish protein. タラ目に属する魚の魚肉タンパク質又は前記魚肉タンパク質のタンパク質分解酵素分解物を含有する、遅筋を速筋タイプに変化させる筋肉増強用食品組成物。   A food composition for enhancing muscles, which comprises fish protein of a fish belonging to the order of Cod or a proteolytic enzyme degradation product of the fish protein, wherein the slow muscle is changed to a fast muscle type. 請求項1又は2の食品組成物を含有し、速筋特異的な筋肉増強作用を有する旨の表示又は遅筋を速筋に変化させる作用を有する旨の表示を付した筋肉増強用食品。 Claim 1 or containing a second food composition, fast twitch specific muscle potentiation muscle-building food marked with indication that alter the fast twitch display or slow-twitch indicating with. 請求項1又は2の食品組成物を含有する食品を、前記食品が速筋特異的な筋肉増強作用を有すること、又は遅筋を速筋に変化させる作用を有することを記載した説明書と共にパッケージした筋肉増強用製品。 A package containing the food composition comprising the food composition of claim 1 or 2 together with instructions describing that the food has a fast muscle-specific muscle-enhancing action or an action that changes the slow muscle to a fast muscle. Products for strengthening muscles .
JP2015220824A 2010-08-26 2015-11-10 Muscle enhancer Active JP6109909B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010190137 2010-08-26
JP2010190137 2010-08-26
JP2011108817 2011-05-13
JP2011108817 2011-05-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012530734A Division JP5838161B2 (en) 2010-08-26 2011-08-26 Muscle enhancer

Publications (2)

Publication Number Publication Date
JP2016073292A JP2016073292A (en) 2016-05-12
JP6109909B2 true JP6109909B2 (en) 2017-04-05

Family

ID=45723564

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012530734A Active JP5838161B2 (en) 2010-08-26 2011-08-26 Muscle enhancer
JP2015220824A Active JP6109909B2 (en) 2010-08-26 2015-11-10 Muscle enhancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012530734A Active JP5838161B2 (en) 2010-08-26 2011-08-26 Muscle enhancer

Country Status (2)

Country Link
JP (2) JP5838161B2 (en)
WO (1) WO2012026575A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102171663B1 (en) * 2020-07-28 2020-11-02 주식회사 씨웰 Source of cod pill protein containing active ingredients of herbal medicines and manufacturing method thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5947177B2 (en) * 2012-09-21 2016-07-06 日本水産株式会社 Preventive or therapeutic agent for disuse muscle atrophy
JP5925391B2 (en) * 2013-10-16 2016-05-25 日本水産株式会社 Peptide or acid addition salt thereof, food and drink, and composition for diabetes prevention, etc.
JP2018519322A (en) * 2015-06-30 2018-07-19 フイルメニツヒ ソシエテ アノニムFirmenich Sa Marine peptides and muscle health
JP2017057175A (en) * 2015-09-18 2017-03-23 株式会社保健科学研究所 Muscle building agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274414A1 (en) * 1999-06-11 2000-12-11 Universite Laval Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals
JP2001069949A (en) * 1999-09-06 2001-03-21 Nippon Meat Packers Inc Decomposed pork and food containing the same
US6333063B2 (en) * 1999-12-28 2001-12-25 Kikkoman Corporation High-protein food of plate form
JP2002053489A (en) * 2000-08-07 2002-02-19 Kaken Pharmaceut Co Ltd Muscle-building agent / Prevention / treatment agent for muscle attenuation
EP1604671A4 (en) * 2003-02-26 2006-03-29 Kyowa Hakko Kogyo Kk MUSCLE TRAINING AGENT AND PREVENTION AND CARE PROVIDER IN THE EVENT OF MUSCLE DEGREASING
JP2005261203A (en) * 2004-03-16 2005-09-29 Japan Science & Technology Agency Methods for screening for drugs that improve the composition and amount of skeletal muscle
EP1940518A4 (en) * 2005-09-09 2009-10-21 Murray Goulburn Coop Co Ltd Milk derived composition and use to enhance muscle mass or muscle strength
WO2007069716A1 (en) * 2005-12-16 2007-06-21 Nippon Suisan Kaisha, Ltd. Composition having effect of inhibiting visceral fat accumulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102171663B1 (en) * 2020-07-28 2020-11-02 주식회사 씨웰 Source of cod pill protein containing active ingredients of herbal medicines and manufacturing method thereof

Also Published As

Publication number Publication date
JPWO2012026575A1 (en) 2013-10-28
JP2016073292A (en) 2016-05-12
JP5838161B2 (en) 2015-12-24
WO2012026575A1 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
JP6109909B2 (en) Muscle enhancer
KR102240196B1 (en) Novel lactobacillus paracasei strain
JP2009173634A (en) LIPID ABSORPTION INHIBITOR CONTAINING POLY-gamma-GLUTAMIC ACID
Liu et al. Hydrolyzed peptides from purple perilla (Perilla frutescens L. Britt.) seeds improve muscle synthesis and exercise performance in mice
KR20210063728A (en) Fermented kiwi powder for improving bowel function and method of preparing the same
WO2016100774A1 (en) Grape products for nonalcoholic fatty liver disease and other uses
US20100035810A1 (en) Adiponectin production enhancer
US8921310B2 (en) Method for accelerating mammalian body fat metabolism
CN114128890A (en) Nutritional supplement composition
CN102892423B (en) Composition for promoting production of adiponectin
JP2006304792A (en) Visceral fat accumulation suppression food
JP2010105946A (en) Muscle protein enhancer and drug or food containing the same
JP5156330B2 (en) Adipose tissue weight reducing agent
WO2015022962A1 (en) Lipid metabolism accelerator
JPWO2018207741A1 (en) PGC-1α biosynthesis promoter and inhibitor for slow muscle fast muscle formation
JPWO2015022962A6 (en) Lipid metabolism promoter
JP7620270B2 (en) Mitochondrial function activator
KR102575452B1 (en) Microorganism strain having activity of improving liver function and use thereof
JP5870181B1 (en) Serum cholesterol level and / or blood lipid level improver
JP5006577B2 (en) Lifestyle-related disease remedy
JP6418579B2 (en) Lipid absorption promoter containing protein degradation product of scallop mantle membrane as active ingredient and food and drink containing the same
JP2013124222A (en) Visceral fat reducing agent
JP2008179609A (en) Blood adiponectin increasing agent
Manzoni et al. Dermatosis and Nutritional Disorders
KR20260025561A (en) Pharmaceutical composition for treating liver disease and improving insulin resistance and method for preparing the pharmaceutical composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170308

R150 Certificate of patent or registration of utility model

Ref document number: 6109909

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250